Molecular Diagnostics News and Research

RSS

'Molecular Diagnostics Europe' conference debuts at BIOTECHNICA 2010

BIOTECHNICA, Europe's Leading Exhibition for Biotechnology and Life Sciences, is broadening its portfolio to include a new conference and special display on molecular diagnostics. Produced by the Cambridge Healthtech Institute, a leading organizer of biomedical conferences in the United States, the "Molecular Diagnostics Europe" (MDxEU) conference is making its debut this year. The main focus will be on new methods for molecular diagnostics, particularly with regard to cancer and infectious diseases.

27 Aug 2010

Luminex launches FDA-cleared xTAG Cystic Fibrosis 60 Kit v2 diagnostic test

Luminex Corporation, the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.

From Thermo Fisher Scientific Inc. 27 Aug 2010

CHI teams with BioFortis to focus on personalized healthcare initiatives for community hospitals

Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.

25 Aug 2010

IVD Technology to launch first annual Virtual Conference and Tradeshow

IVD Technology, the only trade media brand designed exclusively for manufacturers of in vitro diagnostic products, today announced the launch of its first annual Virtual Conference and Tradeshow to be held on September 28, 2010.

24 Aug 2010

Swift Biosciences completes $3 million Series A financing

Swift Biosciences Inc., a Michigan-based life sciences company, today announced the recent completion of a $3 million Series A financing led by the venture firm DFJ Mercury. DFJ Mercury was joined in the Series A by several Michigan-based individual investors who also helped launch the Company with seed funding in January 2010. Daniel Watkins of DFJ Mercury will join the company's Board of Directors.

12 Aug 2010

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.

11 Aug 2010

Myriad Genetics fourth-quarter revenues increase 9% to $93.9 million

Myriad Genetics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2010.

11 Aug 2010

Clarient receives patent for Mammostrat breast cancer prognostic test

Clarient, Inc. a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United States Patent and Trademark Office and the European Patent Office have allowed patents covering the technology behind Clarient Insight Dx Mammostrat, a test designed to aid in the classification of the risk of recurrence of breast cancer following surgery and initial treatment.

11 Aug 2010

Nanosphere reports net loss of $13.8M for second-quarter 2010

Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the second quarter ended June 30, 2010.

6 Aug 2010

New MIC platform measures cell-signaling pathways in brain tumor samples at single-cell level

New technologies for the diagnosis of cancer are rapidly changing the clinical practice of oncology. As scientists learn more about the molecular basis of cancer, the development of new tools capable of multiple, inexpensive biomarker measurements on small samples of clinical tissue will become essential to the success of genetically informed and personalized cancer therapies.

4 Aug 2010

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

What As scientists understand more about a tumor's underlying biology, personalized medicine is emerging as the new patient management paradigm. This year, the American Association for Cancer Research will host its fourth Molecular Diagnostics in Cancer Therapeutic Development: Challenges and Horizons conference at the Sheraton Denver Downtown Hotel in Denver, Colo. This meeting regularly draws representatives from academia and industry to discuss the latest in diagnostic tools and emerging therapies.

4 Aug 2010

Caliper Life Sciences second-quarter GAAP revenue decreases 10% to $29.0 million

Caliper Life Sciences, Inc., today reported results for its second quarter ended June 30, 2010. Second quarter GAAP revenue decreased 10% to $29.0 million from $32.1 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 4% on a reported basis and 6% on an organic basis (which assumes constant currency).

3 Aug 2010

IRIS International closes AlliedPath acquisition

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has closed the acquisition of AlliedPath, Inc., a private, early stage high complexity, CLIA-certified laboratory focused on oncology and molecular diagnostics.

2 Aug 2010

Pathwork Diagnostics enters into research collaboration with Novartis

Pathwork Diagnostics Inc., a molecular diagnostics company focused on oncology, today announced that it has entered into a research collaboration with Novartis. The parties intend to discover clinically meaningful biomarker signatures that can serve as the basis for diagnostics across a range of cancer types. Under the terms of the agreement, both parties have rights to develop and commercialize the diagnostic products. Financial terms were not disclosed.

31 Jul 2010

Roche to present diagnostics testing solutions at 2010 Clinical Lab Expo

Roche is featuring a diverse portfolio of diagnostics testing solutions for healthcare professionals in booth #2808 at the AACC/CSCC 2010 Clinical Lab Expo here, July 27-29 – and it's giving them a unique way to see firsthand where their own "dream lab" might take them.

From Roche Sequencing and Life Science 28 Jul 2010

NIH awards Akonni $435K to develop point-of-care diagnostics for multi-drug resistant strains of MTB

Akonni Biosystems a molecular diagnostics company focused on developing and manufacturing rapid, high multiplex solutions for infectious disease testing, today announced receipt of a $435K grant from the National Institutes of Biomedical Imaging and Bioengineering at the National Institutes of Health. The award will enable Akonni to accelerate development of its hands-free, sample-to-answer system for identifying a broader range of multi-drug resistant strains of Mycobacterium tuberculosis.

28 Jul 2010

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

Asuragen, Inc. announced today the results from two collaborative studies, one with the University of California Davis M.I.N.D. Institute and another with Rush University Medical Center, that demonstrate comprehensive molecular profiling of the Fragile X Mental Retardation (FMR1) gene using advanced PCR-based methods.

26 Jul 2010

Vermillion to complete relocation of corporate offices to Austin, Texas by September 2010

Vermillion, Inc., a molecular diagnostics company, today announced that it is relocating its corporate headquarters from Fremont, California to Austin, Texas. Vermillion has executed a two-year lease for a new principal place of business at 12117 Bee Cave Road, Building Two, Suite 100, Austin, TX 78731. Vermillion will continue to operate research and development, regulatory and quality operations in California. All other functions will be conducted at the Austin offices.

23 Jul 2010

ARUP announces new version of Septin 9 methylated DNA test

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced it is offering the Septin 9 methylated DNA test, a new blood-based colorectal cancer screening method. While ARUP is not the first laboratory to offer this test, this new version, developed and validated independently by ARUP, is clinically proven to detect a higher proportion of colorectal cancers than Septin 9 tests developed by other companies.

20 Jul 2010

Corgenix, ELITech establish broad strategic alliance

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and the ELITech Group, a Paris, France-based, privately held group of companies and worldwide manufacturer and distributor of in-vitro diagnostic equipment and reagents, today announced a broad strategic alliance.

19 Jul 2010

Molecular Diagnostics News and Research

'Molecular Diagnostics Europe' conference debuts at BIOTECHNICA 2010

Luminex launches FDA-cleared xTAG Cystic Fibrosis 60 Kit v2 diagnostic test

CHI teams with BioFortis to focus on personalized healthcare initiatives for community hospitals

IVD Technology to launch first annual Virtual Conference and Tradeshow

Swift Biosciences completes $3 million Series A financing

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

Myriad Genetics fourth-quarter revenues increase 9% to $93.9 million

Clarient receives patent for Mammostrat breast cancer prognostic test

Nanosphere reports net loss of $13.8M for second-quarter 2010

New MIC platform measures cell-signaling pathways in brain tumor samples at single-cell level

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

Caliper Life Sciences second-quarter GAAP revenue decreases 10% to $29.0 million

IRIS International closes AlliedPath acquisition

Pathwork Diagnostics enters into research collaboration with Novartis

Roche to present diagnostics testing solutions at 2010 Clinical Lab Expo

NIH awards Akonni $435K to develop point-of-care diagnostics for multi-drug resistant strains of MTB

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

Vermillion to complete relocation of corporate offices to Austin, Texas by September 2010

ARUP announces new version of Septin 9 methylated DNA test

Corgenix, ELITech establish broad strategic alliance

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News